drugset
drugset / Trial / NCT03955211

HTX-011 Administration Study in Planned Caesarean Section Procedure

NCT03955211 ↗

Phase 2 Completed 25 enrolled Heron Therapeutics
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, open-label study to evaluate the PK and safety of HTX-011 in women undergoing a planned C-section.

Timeline

Start
2019-06-24
Primary completion
2021-12-03
Completion
2021-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject HTX-011 Unknown 300 mg Other
Subject HTX-011 Unknown 400 mg Other
Background Acetaminophen Small molecule 975 mg —
Background Acetaminophen Small molecule 1 g —
Background Ibuprofen Small molecule 400 mg —

Indications

No indication recorded.